| Literature DB >> 26239470 |
Sara C Spielman1, Jennifer S LeBovidge2,3, Karol G Timmons4, Lynda C Schneider5,6.
Abstract
Multidisciplinary interventions have been developed for patients with atopic dermatitis (AD) and their families, with the aim of improving outcomes such as disease control, adherence, and quality of life. We reviewed the content of different multidisciplinary approaches to intervention for AD and evidence for their impact on key outcome measures. We also provided data from our multidisciplinary outpatient program for pediatric AD. Studies included in the review suggest benefits of multidisciplinary interventions as models of treatment or adjuncts to standard medical care, with a positive impact on outcomes including disease severity and itching/scratching. There were limitations to existing studies, including heterogeneous methods used to assess quality of life outcomes across studies and lack of controlled studies assessing the outcome of clinical care programs. Further research will be useful in assessing the impact of multidisciplinary interventions on important outcomes such as treatment adherence and sleep, identifying the elements of multidisciplinary interventions that are most critical for improved outcomes, and identifying the best candidates for multidisciplinary intervention approaches.Entities:
Keywords: atopic dermatitis; eczema; education; interdisciplinary; multidisciplinary; quality of life; treatment
Year: 2015 PMID: 26239470 PMCID: PMC4470222 DOI: 10.3390/jcm4051156
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Summary of outcomes for studies of multidisciplinary interventions for atopic dermatitis.
| Authors | Study Design/Intervention | AD Severity | Itching and Scratching | Itch-Coping Patterns | Quality of Life (Qol) | Healthcare Use/Cost | Adherence |
|---|---|---|---|---|---|---|---|
| Staab | Randomized controlled trial | No significant difference in change in SCORAD ratings between treatment and control groups | Not assessed | Not assessed | Greater improvement in confidence in treatment for treatment group; no other significant differences in QoL between treatment and control groups | Greater reduction in medical consultation and prescription costs for treatment group | More consistent skincare and greater improvement in skincare adaptation based on skin severity (appropriate use of steroids, antiseptics) for treatment group |
| Group educational program for parents | |||||||
| Staab | Randomized controlled trial | Greater improvement in SCORAD ratings for treatment group | Not assessed | Greater reductions in catastrophizing (8–12 and 13–18 year olds) and improvement in coping (8–12 year olds) for treatment group | Greater improvement in QoL for treatment group | Not assessed | Not assessed |
| Group educational program for parents and pediatric patients | |||||||
| Ricci | Pre-post comparison | Not assessed | Not assessed | Not assessed | Improvement in parental and child QoL from start to end of treatment | Not assessed | Not assessed |
| Group educational program for parents | |||||||
| Bostoen | Randomized controlled trial | For AD patients, no significant difference in change on EASI or SCORAD ratings between treatment and control group | Not assessed | Not assessed | For AD patients, no significant difference in change in QoL scores between treatment and control group | No significant differences in medication use or health-care costs (medications, doctor visits) between treatment and control groups | Not assessed |
| Group education program for adult patients with AD or psoriasis | |||||||
| Ehlers | Randomized controlled trial | Greater improvement in severity (body surface affected and lesion severity) for DEBT group than DE or standard medical care | Greater reduction in itching and scratching frequency for DEBT than DE; no significant differences in itch/scratch intensity between groups | Greater reduction in catastrophizing than standard medical care | Not assessed | Greater reduction in topical steroid use for DEBT group than DE alone | Not assessed |
| 4 different group treatment programs * for adult patients | |||||||
| Evers | Controlled trial | Greater improvement in EASI ratings for treatment group | Greater reductions in itch intensity and duration and scratching frequency and duration for treatment group | Greater reductions in catastrophizing and improvement in self-efficacy for treatment group | No significant differences in change in QoL between treatment and control groups | Reductions in dermatology visits and medication use for treatment group | Not assessed |
| Group itch-training intervention for adult patients | |||||||
| Boguniewicz | Descriptive | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed |
| Day treatment program for pediatric patients | |||||||
| LeBovidge | Descriptive | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed |
| Outpatient program for pediatric patients | |||||||
| Chou | Descriptive/chart review | Majority of patients demonstrated improvement in EASI ratings from baseline to follow-up visits | Not assessed | Not assessed | Not assessed | Not assessed | Not assessed |
| Outpatient program for pediatric patients |
Abbreviations used: EASI (Eczema Area and Severity Index) [40], SCORAD (Scoring Atopic Dermatitis) [42]; * Four groups include: DE = dermatological education program, AT = autogenic training (relaxation therapy alone); BT = cognitive-behavioral therapy, DEBT = multidisciplinary combined DE and BT.